BioMarin Pharmaceutical Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio29.35108.34135.8718.64
Forward P/E17.8638.9839.0085.7875.56
P/S Ratio4.397.519.188.798.56
P/B Ratio2.213.674.183.803.88
Price/Tangible Book2.444.104.734.414.56
Price/FCF25.70290.28350.0677.63
Price/OCF21.87114.04109.3453.26186.47
PEG Ratio0.721.070.862.661.75
Enterprise Value Ratios
EV/Revenue4.287.509.098.798.56
EV/EBITDA18.3062.49121.62481.221186.81
EV/EBIT21.4097.60348.42
EV/FCF25.03289.80346.7477.67
Profitability & Returns
Return on Equity (ROE)0.08%0.04%0.03%-0.02%0.24%
Return on Assets (ROA)0.05%0.02%0.01%-0.01%-0.01%
Return on Invested Capital (ROIC)0.09%0.04%0.01%-0.02%-0.02%
Return on Capital Employed (ROCE)0.09%0.03%0.01%-0.01%-0.02%
Leverage & Solvency Ratios
Debt/Equity0.110.230.240.260.28
Debt/EBITDA0.933.736.5823.5643.10
Debt/FCF1.3018.1220.385.38
Liquidity Ratios
Current Ratio5.332.514.674.164.75
Quick Ratio2.961.452.982.543.07
Efficiency Ratios
Asset Turnover0.410.370.340.310.35
Inventory Turnover0.500.530.601.491.67
Yield & Distribution Ratios
Earnings Yield0.03%0.01%0.01%0.00%0.05%
FCF Yield0.04%0.00%0.00%0.01%0.00%
Buyback Yield-0.03%-0.01%-0.03%0.05%-0.07%